S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
NFLX   326.00 (-3.58%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
NFLX   326.00 (-3.58%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
NFLX   326.00 (-3.58%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
NFLX   326.00 (-3.58%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

EU's official: No-deal is more harmful for Britain than EU

Posted on Thursday, January 9th, 2020 By The Associated Press

BRUSSELS (AP) — The European Union’s chief Brexit negotiator said Thursday that if Britain wants as much access as possible to the bloc's market after it leaves, it won't have unfettered freedom to subsidize its industry.

Michel Barnier also insisted that the state aid rules in any future trade deal would be more stringent than with nations like Canada or Japan, simply because of the physical proximity of the departing EU nation.

“If the U.K. wants an open link with us for the products — zero tariffs, zero quotas — we need to be careful about zero dumping at the same time," Barnier told a conference in Stockholm.

“I hope that this point is, and will be correctly understood by everybody. We will ask necessarily certain conditions on state aid policy in the U.K.," Barnier said, adding that if that is not the case, access to the lucrative EU market will be negatively affected.

The EU has been stressing the need for a level playing field in the upcoming trade deal negotiations, meaning that access will be strictly linked to commitments to social welfare and environmental standards, among others. On Thursday, he stressed the need for state aid limits too.

As a member state, Britain was bound by strict state aid rules enforced by the powerful European Commission to make sure there would be no unfair competition among EU nations in its vast single market. Third countries aren't immediately bound by such strictures.

Britain has decided to leave the EU by Jan. 31, partly because it doesn't want to be tied down by EU rules, which it feels impedes its sovereignty. But negotiating a trade deal will still involve many compromises on rule setting.

Barnier also insisted that Britain's goal to have a full free trade deal by the end of the year was unrealistic.

“We cannot expect to agree on every aspect of this new partnership,” Barnier said, adding “we are ready to do our best in the 11 months.”

During a transition period ending Dec. 31, a new relationship between the EU and the U.K. will be negotiated. Full trade covers everything from fisheries to the airline industry to medicines, but the EU insists to deal with all these issues in one year is a pipe dream.

British Prime Minister Boris Johnson has insisted he won’t agree to any more delays — a vow that has set off alarm bells among businesses, which fear that means the country will face a “no-deal” Brexit at the start of 2021.

___

Follow AP’s full coverage of Brexit and British politics at https://www.apnews.com/Brexit

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel